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httpcense.Abstract Aim: Study degree of sensitivity and speciﬁcity of IFN-c as QuantiFERON-TB Gold
In-Tube assay in diagnosis of tuberculosis instead of tuberculin test.
Subjects and methods: Forty patients were included in this study subdivided into two groups.
First included 20 patients with sputum positive for tuberculosis, while the second included 20
patients suspected to catch TB infection, guided by: clinical and radiological examinations with
smear negative for TB. Control group included 10 clinical and radiological healthy controls previ-
ously vaccinated by BCG with positive tuberculin test. All subjects were submitted for full clinical
history physical examination routine laboratory tests, plain chest X-ray, sputum study for acid fast
Bacilli by Ziehl–Neelsen stain, tuberculin test using Mantoux technique, sputum culture on Lowen-
stein-Jensen Medium and QuantiFERON-TB Gold In-Tube (QFT-Gold IT) assay.
Results: QFT-Gold IT test sensitivity = 100% speciﬁcity = 100% predictive value posi-
tive = 100% which means that 100% of the disease positive patients gave positive QFT-Gold IT
test and predictive value negative = 100% which means that 100% of the disease negative patients1222758380, mobile: + 20
hoo.ck.uk (Y.M. Ismail),
ohammad).
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138 S.A. Abdel-Samea et al.gave negative QFT-Gold IT test. Agreement between tuberculin test and QFT-Gold IT test was
good agreement where the ‘j’ was 0.65 (CI = 0.39–0.91). Study revealed positive correlation
between QuantiFERON level and severity of infection in sputum, which was statistically signiﬁcant,
where ‘r’ was 0.92 and P-value was <0.05.
Conclusion: QFT-Gold IT, has excellent sensitivity and speciﬁcity unaffected by BCG vaccina-
tion. Tuberculin test speciﬁcity is high in non-BCG-vaccinated populations but low and variable
in BCG vaccinated populations.
ª 2013 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. Open access under CC BY-NC-ND license.Introduction
One-third of the world’s population is believed to be latently
infected with Mycobacterium tuberculosis, the etiological agent
of tuberculosis (TB), supported by the human immunodeﬁ-
ciency virus type I (HIV-1) pandemic and emerging multidrug
resistance, underlines the need for new control measures and
strategies to make a speciﬁc diagnosis and prevent transmis-
sion [17] although the tuberculin skin test (TST) is the method
of choice for detecting latent M. tuberculosis infection (LTBI),
it cannot be considered a gold standard because of the number
of false-positive and negative reactions, and the variability of
their interpretation [2].
New in vitro tests based on an ability to detect the gamma
interferon (IFN-c) released by activated T lymphocytes have
recently been proposed [30]. These assays use antigens speciﬁc
for M. tuberculosis, such as early secretory antigenic target 6
(ESAT-6) and culture ﬁltrate protein 10 (CFP-10), which are
two low-molecular-mass secretory proteins encoded by genes
located within region of difference I (RD 1) of the M. tubercu-
losis genome [8,36]. All of the vaccine strains of BCG and most
of nontuberculous mycobacteria (NTM) are not prevalent in
this region, with the exception of Mycobacterium kansasii,
Mycobacterium marinum, and Mycobacterium szulgai [24].
These proteins and the synthetic overlapping peptides corre-
sponding to the full length of each elicit a strong T-cell re-
sponse in animal models of TB [38] and human with active
TB infection [34,39] or LTBI [35].
The QuantiFERON-TB assay (Cellestis Limited, Carnegie,
Victoria, Australia) and the T-SPOT TB assay (Oxford Immu-
notec, Oxford, United Kingdom) are two commercial IFN-c
assays, and a number of in-house assays have also been as-
sessed [3,30].
Aim of the work
The aim of this work was to study the degree of sensitivity and
speciﬁcity of using IFN-c as QuantiFERON-TB Gold In-Tube
(QFT-Gold IT) assay (Cellestis Limited, Carnegie, Victoria,
Australia) in diagnosis of infected population withM. tubercu-
losis instead of the tuberculin skin test (TST), as one of the
new diagnostic methods also not affected by BCG vaccination
so that it can be possible to create new control measures and
strategies tomake a speciﬁc diagnosis and prevent transmission.
Patients, materials and methods
Forty patients attending to Benha University hospital outpa-
tient clinics were included in this study. Full clinical evaluationwas undertaken including a full clinical and family history,
physical examination, and routine laboratory tests.
Patients were subdivided into two groups. The ﬁrst group
included 20 patients with sputum positive for M. tuberculosis
(TB) infection, while the second group included 20 patients
suspected to catch TB infection, guided by: clinical examina-
tions (symptoms and signs) and radiological studies with smear
negative for TB. Control group included 10 age and sex
matched clinical and radiological healthy controls previously
vaccinated by BCG with positive tuberculin test.
The patients and controls were subjected for full clinical
evaluation including a full clinical and family history, physical
examination, and routine laboratory tests, plain chest X-ray
(P.A. and lateral view), sputum study for acid fast Bacilli by
Ziehl–Neelsen stain, tuberculin skin test (TST) using Mantoux
technique, sputum culture on conventional Lowenstein-Jensen
medium. The ready to use media for the primary isolation and
identiﬁcation of mycobacteria particularly M. tuberculosis was
obtained from DIFCO Laboratories named the Bacto-Lowen-
stein medium.
QuantiFERON-TB Gold In-Tube (QFT-Gold IT) assay
(Cellestis Limited, Carnegie, Victoria, Australia) was done as
follows: a total 3 ml of blood was collected from each subject,
with 1 ml directly collected into each of 3 colored tubes in the
order of gray (negative control, ‘‘nil’’), red (test tube), and pur-
ple (positive control; mitogen-coated) tubes. The test tube is a
speciﬁcally designed blood collection tube coated with Mtb-
speciﬁc antigens (ESAT-6, CFP-10, and a portion of TB
7.7). Tubes were incubated at 37 C. Following a 16–24 h incu-
bation period, the tubes were centrifuged, the plasma is re-
moved and the amount of IFN-c (IU/ml) measured by
ELISA. The results were tabulated and statistically analyzed.
A test was considered positive for an IFN-c response to the
TB antigen tube that is signiﬁcantly above the Nil IFN-c IU/
ml value. The IFN-c value for TB-speciﬁc antigens was cor-
rected by subtracting the value obtained for the respective neg-
ative controls; the test was considered positive if the IFN-c
level was above the cutoff test value (P0.35 IU/ml). The mito-
gen-stimulated plasma sample serves as an IFN-c positive con-
trol for each specimen tested. A low response to mitogen
(<0.5 IU/ml) indicates an indeterminate result when a blood
sample also has a negative response to the TB antigens. Exclu-
sion criteria included subjects with history of recent viral infec-
tions e.g. Inﬂuenza and hepatitis, history of long use of
corticosteroid or cytotoxic drugs, those who were suspected
to be immunocompromized e.g. patients with diabetes melli-
tus, renal failure or liver cell failure.
Data were statistically described in terms of range,
mean ± standard deviation (±SD), median, frequencies
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QuantiFERON and Tuberculin Test in Diagnosis of TB 139Comparison of quantitative variables between the study
groups was done using Mann Whitney U test for independent
samples. For comparing categorical data, Chi square (v2) test
was performed. Exact test was used instead when the expected
frequency is <5. Odds ratio (OR) was calculated as a measure
of association for polymorphism and allelic presence between
cases and control groups. A probability value (P value) less
than 0.05 was considered statistically signiﬁcant. All statistical
calculations were done using computer programs Microsoft
Excel 2003 (Microsoft Corporation, NY, USA) and SPSS
(Statistical Package for the Social Science; SPSS Inc., Chicago,
IL, USA) version 15 for Microsoft Windows.Figure 1 Correlation between Quantiferon level and severity of
infection in sputum.
Table 2 Patient clinical variables.
Characteristic Group 1 Group 2 P value (%)
Number % Number %
Chronic cough 9 45 5 25 >0.05
Hemoptysis 3 15 1 5 >0.05
Toxemia 12 60 3 15 >0.05
Crepitations 13 65 5 25 >0.05
Signs of toxemia 5 25 1 5 >0.05
X-ray ﬁndings 5 25 1 5 >0.05Results
Regarding clinical variables among studied groups, 9 patients
(45%) of group I had chronic cough, 3 patients (15%) had
hemoptysis and 12 patients (60%) had toxemia. As for group
II: 5 patients (25%) had chronic cough, 1 patient (5%) had
hemoptysis and 3 patients (15%) had toxemia. Comparison
between group I and group II according to symptoms was sta-
tistically insigniﬁcant as shown in as P-value was >0.05.
According to signs: 13 patients (65%) of group I had crepita-
tions and 5 patients (25%) had signs of toxemia. As for group
II: 5 patients (25%) had crepitations and 1 patient (5%) had
signs of toxemia. Comparison between group I and group II
according to signs was statistically insigniﬁcant as shown in
(Table 1) as P-value was >0.05.Discussion
The QuantiFERON-TB Gold assay is an enzyme-linked
immunosorbent assay (ELISA) that measures the production
of interferon gamma (IFN-c) by T-cells after sensitization with
M. tuberculosis antigens using whole blood [6,26,18]
(Fig. 1,Tables 2–6 and 8).
This work aimed to study the degree of sensitivity and spec-
iﬁcity of using IFN-c as QuantiFERON-TB Gold In-Tube
(QFT-Gold IT) assay (Cellestis Limited, Carnegie, Victoria,
Australia) in diagnosis of infected population withM. tubercu-
losis instead of the tuberculin skin test (TST), as one of the new
diagnostic methods so that it can be possible to create new
control measures and strategies to make a speciﬁc diagnosis
and prevent transmission.
The age in group I was 28.4 ± 4.7 years, in group II was
27.3 ± 5.1 years, and in control was 28.9 ± 4.6 years. It was
noticed that all groups were age matched and there were no
statistical differences between them.
This study revealed that, the results of tuberculin test and
Z.N. in diseased groups was:
In group I: 16 patients were positive by tuberculin test and
all of them were positive by Z.N., and 4 patients were neg-
ative by tuberculin test, while they were positive by Z.N.Table 1 Comparison between different groups according to age.
Group 1 X ± SD Group2
Age (Years) 28.4 ± 4.7 27.3 ± 5In group II: 12 patients were positive by tuberculin test and
all of them were negative by Z.N., and 8 patients were neg-
ative by tuberculin test, and all of them were negative by
Z.N.
In group I: male patients were 15 (30%) while female pa-
tients were 5 (10%), in group II: male patients were 13
(26%) while female patients were 7 (14%) and in control: male
patients were 8 (16%) while female patients were 2 (4%). It
was noticed that all groups were sex matched and there were
no statistical differences between them.
Evaluation of tuberculin test as a diagnostic test in relation
to culture showed that: tuberculin test sensitivity = 94.7%,
speciﬁcity = 80%, positive predictive value (PPV) = 90%
which means that 90% of the disease positive patients gave po-
sitive tuberculin test and negative predictive value
(NPV) = 66.7% which means that 66.7% of the disease nega-
tive patients gave negative tuberculin test.
In our results, there was a positive correlation between
Quantiferon level and severity of infection in sputum, which
was statistically signiﬁcant, where ‘r’ was 0.92 and P-value
was <0.05.
Evaluation of QFT-Gold IT test as a diagnostic test for TB
in relation to culture showed that: QFT-Gold IT test sensitiv-
ity = 100%, speciﬁcity = 100%, positive predictive value
(PPV) = 100% which means that 100% of the disease positive
patients gave positive QFT-Gold IT test and negative predic-
tive value (NPV) = 100% which means that 100% of theX± SD Control X ± SD P-value
.1 28.9 ± 4.6 >0.05
Table 3 Comparison between different groups according to residence.
Group 1 Group 2 Control Total P-value
No. % No. % No. %
Residence Urban 14 28 12 24 7 14 33 >0.05
Rural 6 12 8 16 3 6 17
Table 4 Results of Quantiferon levels in different groups.
Quantiferon levels in diﬀerent tubes (IU/ml)
Antigen Mitogen Nil
Group I 10.85 4.64 0.16
Group II 9.9 4.23 0.22
Control 0.65 2.34 0.14
Table 5 Correlation between Quantiferon and degree of Z.N.
positivity.
Variable r (Correlation coeﬃcient) P-value
Severity of infection
in sputum (smear positivity)
0.92 <0.05
Table 6 Evaluation of QFT-Gold IT test as a diagnostic test
for TB in relation to culture in diseased groups.
Culture Total
+ve ve
QFT-Gold IT +ve 32 0 32
ve 0 8 8
Table 7 Correlation between Quantiferon and diameter of
cavity in X-ray.




Table 8 Agreement between tuberculin test and QFT-Gold
IT.




+ve 36 4 40 0.65
ve 2 8 10 (CI = 0.39–0.91)
Total 38 12 50 Good agreement
140 S.A. Abdel-Samea et al.disease negative patients gave negative QFT-Gold IT test.
Agreement between tuberculin test and QFT-Gold IT test
was a good agreement, where the ‘j’ was 0.65 (CI = 0.39–
0.91). Approximate to our results: in a US study, QuantiFER-
ON-TB Gold IT and TST results were available for 391 volun-
teers. None were BCG vaccinated. QuantiFERON-TB Gold
IT Speciﬁcity was 99.2% while that of TST was 98.5%. A sec-
ond speciﬁcity study was performed with QuantiFERON-TB
Gold IT in low risk individuals in Japan, approximately
90% who had received BCG vaccination, it was 98.4% ([33],
Cellestis). Also TB-suspects from Australia and Japan who
were subsequently conﬁrmed to have M. tuberculosis infection
by culture were tested to evaluate sensitivity of QuantiFER-
ON-TB Gold IT. Overall sensitivity of QuantiFERON-TB
Gold IT for active TB disease was 89% ([33], Cellestis).Similar to our results, in an Indian study of 726 healthcare
workers: there was setting of very high TB rates. There was
40% QFT-Gold IT positive and 41% TST positive. QFT-Gold
IT showed high concordance with TST, no effect of BCG on
either test. Both tests related to risk factors of age and period
of work in healthcare [29].
Also, in a study of 105 hospitalized children in whom TB
was suspected, QFT-Gold IT and TST was done. 10.5%
QFT-Gold IT was positive and 9.5% TST was positive. Agree-
ment between tests was 95.2% overall and 100% in non-BCG
vaccinated [16].
On the other hand, in a study of 309 German contacts: 51%
were BCG vaccinated and 27% foreign born. 70% of BCG
vaccinates and 18% of non-vaccinated were TST positive,
whereas 9% and 11% were QFT-Gold IT positive, respec-
tively. QFT-Gold IT was associated with TB risk. TST was
only associated with BCG vaccination [15].
Similar to our results, QFT results are less subject to reader
bias and error compared with TST. In a CDC-sponsored mul-
ticenter trial, QFT and TST results were moderately concor-
dant (overall kappa value = 0.60). The level of concordance
was adversely affected by prior bacille Calmette–Gue´rin
(BCG) vaccination, immune reactivity to nontuberculous
mycobacteria (NTM), and a prior positive TST [25]. However,
one of the ﬁve sites involved in the CDC study reported less
agreement [7].
In addition to the multicenter study, two other published
studies have demonstrated moderate concordance between
TST and QFT [37,32]. One of the ﬁrst reports that assessed
the liberation of IFN-c after exposure to tuberculin was per-
formed in Australia and showed a speciﬁcity of 98% and a sen-
sitivity of 90% [37]. The other study evaluated
QuantiFERON-TB (QIFN), in 455 individuals from three
groups: group I, 237 immigrants from high-risk countries;
group II, 127 health care workers undergoing Mantoux test-
ing; group III, 91 patients being investigated for possible active
tuberculosis. The QIFN results were compared either to those
of the Mantoux test. For group I, the agreement between
QIFN and Mantoux results was 89% for Mantoux-negative
and 64% for Mantoux-positive individuals. For group II, the
agreement was 81% for Mantoux-negative and 67% for Man-
toux-positive individuals. For group III, agreement was 81%
for Mantoux-negative and 86% for Mantoux-positive patients.
QuantiFERON and Tuberculin Test in Diagnosis of TB 141For patients being evaluated for active tuberculosis, the perfor-
mance of the Mantoux test was not statistically different from
that of the QIFN assay. In patients with active tuberculosis,
the assay had a sensitivity of 77%, not signiﬁcantly higher
for extrapulmonary than pulmonary cases (83% versus
74%). QIFN sensitivity was not signiﬁcantly different for
smear-negative or smear-positive cases (80% versus 71%).
The QIFN assay is a potential replacement for the Mantoux
test. The acceptability of these performance values and those
of similar evaluations could determine the place this test will
have in detecting evidence of mycobacterial infection [32].
Also, a recently published study demonstrated that a posi-
tive IGRA result is predictive of future active TB risk. More-
over, IGRA was at least as sensitive and was more speciﬁc
compared to traditional TST. In this study of immunocompe-
tent recently exposed close contacts of active TB cases, the pro-
gression rate to active disease among untreated QFT positive
individuals was signiﬁcantly greater than for untreated TST
positives (14.6% versus 2.3%). Although the numbers were
small, all of the close contacts who went onto develop active
TB were QFT positive, but only 83% were TST positive [14].
As noted above, prior BCG vaccination can produce false
positive TST results. In a study of military personnel returning
from missions, about one-half of the positive TSTs were falsely
positive [12]. A more recent study of military returning from
missions, reported evidence suggesting false positive TST re-
sults are common and that QFT testing could guide more tar-
geted treatment and alleviate unnecessary anti-tuberculosis
treatment [19].
According to the FDA approved package insert Quanti-
FERON-TB Gold Tube has a consistent speciﬁcity of
>99% in low risk individuals and a sensitivity as high as
92% in individuals with active disease, depending on setting
and extent of disease. The speciﬁcity in two studies of a few
hundred people is 96–98% in a health immunized population
([33], Cellestis).
In a previous study, QuantiFERON-TB test was used to
detect infection in contacts in a tuberculosis outbreak at a
Danish high school. The majority of the contacts were BCG-
unvaccinated, which allowed a direct comparison of the skin
test and the novel blood test in individuals whose skin test
was not confounded by vaccination. An excellent agreement
between the two tests was found (94%, j value 0.866), and
in contrast, the novel blood test was not inﬂuenced by the vac-
cination status of the subjects tested [10].
In countries with a higher prevalence of non-tubercular
mycobacterial infections, the correlation between the tests
may decline; for example, a report from Korea described a
poor correlation between the test in healthy volunteers with
and without risk factors for tuberculosis exposure (j= 0.08–
0.17). Kang and colleagues found 44 out of 54 (81.5%)
patients with active TB were QFT positive, whereas the TST
detected 42 (77.8%). The TST was clearly corrupted by BCG
[21].
Among 785 study participants, interassay agreement be-
tween TST and Interferon-c assays was 89.6% (j= 0.59) [4].
A study that compared the TST with the QFT-G, carried a
sensitivity of 42.2% and a speciﬁcity of 97.9%. The QFT-G
agreed with a positive skin test result for 86.5% [5].
In 129 patients with culture-proven M. tuberculosis disease
the sensitivity of Interferon-Gamma test was 81% compared
to 89% for TST (P= 0.06). When positive responses in bothTST and Interferon-Gamma test were combined, 96% of TB
patients were detected. Interferon-Gamma test may prove an
alternative to skin testing for detecting M. tuberculosis infec-
tion [11].
Results of 30 elderly patients with active TB, 27% had a po-
sitive TST result and 77% had a positive QFT-2G result. Of
100 younger patients with active TB, 70% had a positive
TST result and 87% had a positive QFT-2G result. Although
there was no signiﬁcant difference between the two patient
groups in the positive rate of QFT-2G test (P= 0.185), there
was a signiﬁcant difference in the rates of positive TST result
between elderly and younger patients (P= 0.012). The study
conﬁrmed that the QFT-2G test might be a more useful meth-
od of diagnosing TB infection than the TST test for elderly pa-
tients [22].
Data for 207 children with valid tuberculin skin test and
QuantiFERON-TB Gold In-Tube test results were analyzed.
There was an excellent correlation between negative tuberculin
skin test results and negative QuantiFERON-TB Gold In-
Tube test results; however, only 23% of children with positive
tuberculin skin test results had positive QuantiFERON-TB
Gold In-Tube test results. The study conﬁrmed that the Quan-
tiFERON-TB Gold In-Tube test is a speciﬁc test for M. tuber-
culosis exposure in children, with performance characteristics
similar to those for adults residing in regions with low levels
of endemic disease [23].
Another study compared the effectiveness of the Quanti-
FERON-TB Gold (QFT) assay with the Mantoux tuberculin
skin test to detect M. tuberculosis infection in 29 children dur-
ing a school outbreak of tuberculosis. Of the 21 children with
M. tuberculosis infection, 11 had a radiograph suggestive of the
infection. The QFT assay was positive in all 21 of the children,
and the Mantoux test was negative at ﬁrst testing in 2 children.
The ﬁndings demonstrated that the QFT test is extremely use-
ful in accurately identifying infected and uninfected children,
permitting rapid intervention [27].
In a study of 938 enrollees from Kenya, 909 had a tubercu-
lin skin test reading, and QuantiFERON-TB assay results and
were included in further analysis. Overall, 553 (61%) had a po-
sitive tuberculin skin test (TST) and 512 (56%) had a positive
QuantiFERON-TB assay. There was substantial agreement
between TST and QuantiFERON-TB assay with a kappa of
0.77 (p> 0.001). A BCG scar was visible on 537 (59%) of
the 909. In these 537 individuals, 387 (72%) had a positive
TST and 339 (63%) a positive QuantiFERON-TB assay again
with a kappa of 0.77 (p> 0.001). In this setting, both methods
were more reactive in BCG vaccinated individuals [1].
On the contrary to our study, 207 Japanese healthcare stu-
dents recruited at Okayama University received both the TST
and the QFT to assess the level of agreement between these
two tests. The agreement between the QFT and the TST results
was poor, with positive result rates of 1.4% vs. 27.5%, respec-
tively. As a baseline screening test for low-risk students at their
course entry, QFT yielded quite discordant results, compared
with the TST, probably because of the low speciﬁcity of the
TST results in the BCG-vaccinated population [20].
A recent Review article incorporated newly reported evi-
dence from 20 studies into an updated meta-analysis on the
sensitivity and speciﬁcity of IGRAs, including studies that
evaluated QuantiFERON-TB Gold, QuantiFERON-TB Gold
In-Tube (both from Cellestis, Victoria, Australia), and T-
SPOT.TB (Oxford Immunotec, Oxford, United Kingdom) or
142 S.A. Abdel-Samea et al.its precommercial ELISpot version, when data on the commer-
cial version were lacking. The pooled sensitivity was 78%
(95% CI, 73–82%) for QuantiFERON-TB Gold, 70% (CI,
63–78%) for QuantiFERON-TB Gold In-Tube, and 90%
(CI, 86–93%) for T-SPOT.TB. The pooled speciﬁcity for both
QuantiFERON tests was 99% among non-BCG-vaccinated
participants (CI, 98–100%) and 96% (CI, 94–98%) among
BCG-vaccinated participants. The pooled speciﬁcity of T-
SPOT.TB (including its precommercial ELISpot version) was
93% (CI, 86–100%). Tuberculin skin test results were hetero-
geneous, but speciﬁcity in non-BCG-vaccinated participants
was consistently high (97% [CI, 95–99%]). The study con-
cluded that the IGRAs, especially QuantiFERON-TB Gold
and QuantiFERON-TB Gold In-Tube, have excellent speciﬁc-
ity that is unaffected by BCG vaccination. Tuberculin skin test
speciﬁcity is high in non-BCG-vaccinated populations but low
and variable in BCG-vaccinated populations. Sensitivity of
IGRAs and TST is not consistent across tests and populations,
but T-SPOT.TB appears to be more sensitive than both Quan-
tiFERON tests and TST [31].
ELISA-IGRA seems to be highly speciﬁc for active tuber-
culosis, as deﬁned by the number of patients without tubercu-
losis who have negative ELISA-IGRA. In 4 studies that
addressed this issue, the speciﬁcity of ELISA-IGRA especially
QFT ranged between 97% and 100% [9,10,28,34]. Mori and
colleagues, found the sensitivity of QFT test to be 89%, with
105 out of 118 patients testing positive, while only 50 out of
70 (65.8%) patients who had also received a TST test were po-
sitive [28].
There was also a positive correlation between Quantiferon
level and cavitations in X-ray, which was statistically signiﬁ-
cant, where ‘r’ was 0.83 and P-value was <0.05 (Table 7). Sim-
ilarly, In the 16th European Congress of Clinical Microbiology
and Infectious Diseases, results showed a generally good agree-
ment between the clinical ﬁndings and the QuantiFERON-TB
test results [13].
Conclusion
QFT-Gold IT has excellent sensitivity and speciﬁcity that is
unaffected by BCG vaccination or other variables. TST speci-
ﬁcity is high in non-BCG-vaccinated populations but low and
variable in BCG-vaccinated populations. There is a good
agreement between the clinical ﬁndings and the QuantiFER-
ON-TB test results.
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